Alumis Inc. (ALMS): Revenue

Annual figures by period end, from SEC filings.

$24.05M

Year ended 2025-12-31

$7.40M

Trailing 12 months to 2026-06-30

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$24.05M	n/a	2026-03-19, From 2025-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Alumis Inc. (ALMS)	2025-12-31	$24.05M	n/a
Entrada Therapeutics, Inc. (TRDA)	2025-12-31	$25.42M	-87.9%
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	$22.50M	-50.6%
Celularity Inc (CELU)	2025-12-31	$26.55M	-51.0%
Cue Biopharma, Inc. (CUE)	2025-12-31	$27.47M	+195.7%
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	$20.71M	-27.4%
Scynexis Inc (SCYX)	2025-12-31	$20.60M	+449.9%
Evofem Biosciences, Inc. (EVFM)	2025-12-31	$20.18M	+4.2%
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	$19.39M	+68.0%

Compare ALMS, TRDA, NAMS, CELU side by side · Screen every company in Pharmaceutical Preparations ↗